Karyopharm Therapeutics Inc   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Natick MA United States (2008)

Organization Overview

First Clinical Trial
2012
NCT01607892
First Marketed Drug
2019
selinexor (Xpovio)
First NDA Approval
2019
selinexor (Xpovio)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Karyopharm Therapeutics Inc | KARYOPHARM THERAPS